– Designation is an important step toward bringing this potentially life-changing therapy to European patients –
– EU Orphan Drug Designation is the first regulatory designation for a gorilla.
– FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and no additional randomized, placebo-controlled trial will be required to support submission of a.
– First FDA Breakthrough Therapy Designation granted for AdenoVerse immunotherapy platform; designation prioritizes PRGN-2012 as a potential treatment for RRP –– . | June 20, 2023
The past 5–10 years have brought in a new era in the care of patients with thyroid
cancer, with the introduction of transformative diagnostic and management options.
Several international ultrasound-based thyroid nodule risk stratification systems
have been developed with the goal of reducing unnecessary biopsies. Less invasive
alternatives to surgery for low-risk thyroid cancer, such as active surveillance and
minimally invasive interventions, are being explored. New systemic therapies are now
available for patients with advanced thyroid cancer.
Unresolved obstructive sleep apnoea (OSA) after an adenotonsillectomy, henceforth
referred to as persistent OSA, is increasingly recognised in children (2–18 years).
Although associated with obesity, underlying medical complexity, and craniofacial
disorders, persistent OSA also occurs in otherwise healthy children. Inadequate treatment
of persistent OSA can lead to long-term adverse health outcomes beyond childhood.
Positive airway pressure, used as a one-size-fits-all primary management strategy
for persistent childhood OSA, is highly efficacious but has unacceptably low adherence
rates.